Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria | Zendy

Sunny Oyakhirome | Zendy; Saadou Issifou | Zendy; Peter Pongratz | Zendy; Fortune Barondi | Zendy; Michael Ramharter | Zendy; Jürgen F. J. Kun | Zendy; Michel A. Missinou | Zendy; Bertrand Lell | Zendy; Peter G. Kremsner | Zendy

Open Access

Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria

Author(s) -

Sunny Oyakhirome,

Saadou Issifou,

Peter Pongratz,

Fortune Barondi,

Michael Ramharter,

Jürgen F. J. Kun,

Michel A. Missinou,

Bertrand Lell,

Peter G. Kremsner

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01448-06

Subject(s) - sulfadoxine , sulfadoxine/pyrimethamine , malaria , clindamycin , plasmodium falciparum , randomized controlled trial , pyrimethamine , medicine , biology , antibiotics , immunology , microbiology and biotechnology

Fosmidomycin-clindamycin therapy given every 12 h for 3 days was compared with a standard single oral dose of sulfadoxine-pyrimethamine. The two treatments showed comparably good tolerabilities and had an identical high degree of efficacy of 94% in a randomized trial carried out with 105 Gabonese children aged 3 to 14 years with uncomplicated malaria. These antimalarials merit further clinical exploration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research